# Jennifer K. Litton

Source: https://onco.cc/people/jennifer-litton/  
OnCo record `jennifer-litton` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jennifer Litton led the EMBRACA trial that brought talazoparib to BRCA-mutated breast cancer.

## Summary

Jennifer Litton is Vice President for Clinical Research and Professor of Breast Medical Oncology at MD Anderson Cancer Center. A breast medical oncologist specialising in BRCA and PARP inhibitors, she was principal investigator of EMBRACA, the trial that brought talazoparib to BRCA-mutated breast cancer, and of neoadjuvant talazoparib studies in germline BRCA carriers. Her papers report talazoparib in advanced breast cancer with a germline BRCA mutation in the New England Journal of Medicine and neoadjuvant talazoparib for operable breast cancer with a germline BRCA pathogenic variant in the Journal of Clinical Oncology. She oversees clinical research operations across MD Anderson, with work spanning triple-negative and HR-positive breast cancer and germline testing.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Vice President, Clinical Research; Professor of Breast Medical Oncology, MD Anderson
- Specialisms: Breast cancer; BRCA; PARP inhibitors

## Sources

- MD Anderson faculty: https://faculty.mdanderson.org/search?q=Jennifer%20K.%20Litton
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Litton%20JK%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Jennifer%20K.%20Litton

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Talazoparib](https://onco.cc/drugs/talazoparib/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- trials: [EMBRACA](https://onco.cc/trials/embraca/)

---
JSON: https://onco.cc/api/v1/entities/jennifer-litton.json